Oral Mucositis Treatment Market Report Scope & Overview:
The oral mucositis treatment market size was valued at USD 1.79 billion in 2024 and is expected to reach USD 3.12 billion by 2032, growing at a CAGR of 7.26% over the forecast period of 2025-2032.
The global oral mucositis treatment market is anticipated to show steady growth as the prevalence of cancer increases and more patients undergo chemotherapy and/or radiotherapy that can induce mucositis. Although traditional treatment methods are effective, shift toward treatments, such as low-level laser therapy, bioadhesive gels, and anti-inflammatory agents that have shown efficacy in improving patient outcomes. Also, favorable growth of this market is due to increased awareness and improved supportive care practices, along with an increase in healthcare investments.
The U.S. Oral Mucositis Treatment Market size was valued at USD 0.54 billion in 2024 and is expected to reach USD 0.93 billion by 2032, growing at a CAGR of 7.03% over the forecast period of 2025-2032.
The U.S. led the North American oral mucositis treatment market owing to the high cancer burden in the nation, high incidence rates associated with chemotherapy/radiation therapy, high prevalence of oral mucositis, and well-established healthcare infrastructure. Robust R&D spending coupled with the rapid uptake of innovative therapies further bolsters the country as a regional leader.
Market Dynamics:
Drivers
-
Increasing Incidence of Cancer is Driving the Market Growth
The growing number of cancer instances globally, predominantly head and neck, blood-related, and gastrointestinal cancers, has directly resulted in increasing cases of oral mucositis. Cancers that are typically treated with chemotherapy and radiotherapy are damaging to rapidly dividing cells, such as the sensitive mucosal lining of the mouth. With the increasing number of people receiving these treatments, more people experience mucositis, leading to an increased requirement for suitable treatment options. This trend is expected to boost the demand for supportive care products for oral mucositis.
One meta-analysis revealed that 99% of nasopharyngeal carcinoma cases who received radiotherapy presented with oral mucositis, highlighting that this side effect is a common complication among head-and-neck cancers.
Oral mucositis was observed in 75–80% of allogeneic hematopoietic stem cell transplant (AHSCT) recipients, with many suffering from grade‑3 or grade‑4 mucositis.
-
The Growth of the Market is Attributed to the Advancements in Treatment Modalities
New treatment concepts for oral mucositis (OM), including low-level laser therapy (LLLT), bioadhesive gels, and cytokine-based formulations, have changed the paradigm of this devastating condition. These therapies provide a quicker response, but they also prevent severe complications and keep patients on track with their cancer treatments. As clinical outcomes improve and healthcare providers adopt these newer, evidence-based solutions, demand and technological evolution in the market continue to feed each other, accelerating growth.
A systematic review of low-level light therapy/LED-based (low-level light therapy) concluded that this was effective in reducing the oral mucositis severity and pain, and also reported faster healing and a better quality of life for the patients.
ScienceDirect publication pointing out the role of low-level laser therapy or PBMT (photobiomodulation), "Low-level laser therapy significantly decreased the severity and duration of oral mucositis, and subjective patient-reported outcomes of oral mucositis in costly cancer treatment cycles"
Newer agents such as palifermin (a keratinocyte growth factor) are still being tested as possible prophylactic therapies, especially in high-risk chemotherapy and radiation protocols.
Restraint
-
The High Cost of Advanced Therapies is Limiting the Market Growth
Novel advanced oral mucositis therapies, including low-level laser therapy (LLLT), biological agents such as palifermin, and specialized protective gels or mouthwashes, offer potentially safe and effective treatment for oral mucositis, but the high cost of these approaches represents a major barrier to their widespread adoption, particularly in low- and middle-income countries. Although they are clinically effective, these therapies often are burdensome due to expensive equipment, multiple applications, or in-hospital administration. Additionally, because most supportive care drugs are only reimbursed within certain categories in certain healthcare systems (and in some systems, have no coverage at all, making them the sole responsibility of the patient), the out-of-pocket cost can be a barrier to access for patients. Consequently, these alternatives, although therapeutic, have low adoption; more limited market expansion occurs in low-resource regions and among economically constrained populations.
Segmentation Analysis:
By Treatment Type
Rapidly reducing the pain and discomfort that is associated with this condition amongst cancer patients receiving chemotherapy and radiotherapy is the immediate medical need; hence, the pain control medication segment held the largest share of the oral mucositis treatment market in 2024, with a 48.3% market share. Symptomatic treatment is mainly provided with medications, which include topical anesthetics, opioids, and non-opioid analgesics. With a rapid onset of action, ease of administration, and a critical aspect of enhancing the quality of life of patients, these therapeutics consolidate and maintain their market dominance.
The mouthwash segment of the global oral care market is expected to grow at the highest rate during the forecast period, owing to the adoption of preventive solutions and supportive care. Antimicrobial, anti-inflammatory, and mucosal coating agents are effective for reducing the duration and severity of mucositis, particularly when used early in a cycle of cancer treatment. Due to their ease of use, affordability, and growing clinical recommendation for routine applications, this market is rapidly growing, especially in outpatient and home-care situations.
By Drug Class
In 2024, the anti-inflammatory segment accounted for the largest share of the oral mucositis treatment market, with a 36.5%, as this treatment is essential for downregulating tissue inflammation and addressing the painful symptoms of mucosal injury induced by cancer therapies. Naturally, corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) are anti-inflammatory agents that are commonly employed to reduce the swelling, redness, and pain for better patient compliance with continuing the cancer treatment. They are widely marketed and established as standard therapy, and clinical efficacy has greatly helped in positioning these products to lead the market.
The antimicrobials segment is poised to register the fastest growth during the forecast years, owing to the rising need to treat patients with obliterated oral mucosa from secondary infections. Since mucositis renders the risk of infections (bacterial, viral, and fungal), the use of antimicrobial agents (i.e., chlorhexidine, benzydamine, and antifungal rinses) as prophylaxis and treatment is on the rise. This segment is rapidly gaining adoption due to the increasing focus on infection control and the increasing utilization of targeted antimicrobial therapies.
By Cause
The chemotherapy segment held the largest market share of the oral mucositis treatment market in 2024, with around 71.4%, as mucositis induced by chemotherapy is one of the most prevalent and consequential adverse effects of anticancer treatment in patients receiving therapy for cancers in the head and neck region, hematological malignancies, and gastrointestinal cancers. Chemotherapy, being cytotoxic, damages the rapidly dividing epithelial cells present in the oral mucosa, resulting in inflammatory changes and ulceration. Chemotherapy has generated a high unmet need for supportive treatment used throughout cancer care and closely related to mucositis, ensuring that its significant market share remains more than the support treatment targeting mucositis led by chemotherapy.
Driven by the increasing prevalence of head and neck cancers and the growing adoption of techniques administering large doses of targeted radiation to the smaller volume of tissue around the tumor, the radiotherapy segment is anticipated to witness the fastest growth in the forecast years. Radiotherapy results in a fractionated tissue injury, which often results in significant and chronic radiomucositis in patients. This, in turn, is leading to rising demand for oral care products as well as preventive therapies focused specifically on the treatment of radiotherapy-induced mucositis. The segment is further propelled by developing radioprotective agents and supportive care measures.
By Distribution Channel
Based on distribution channels, the oral mucositis treatment market is dominated by hospital pharmacy with a 62.5% market share. Patients may also receive immediate, supervised access to pain control medications and anti-inflammatory agents, which, in a clinical setting, are often prescribed by oncologists who can provide relevant care. In addition, moderate to severe cases of mucositis that necessitate intravenous drugs or constant monitoring are managed within an inpatient facility, further solidifying hospital pharmacies' dominant stance in the market.
During the forecast period, the fastest growing segment is expected to be the retail pharmacy segment, which can be attributed to the trend of outpatient treatment of cancer and the presence of over-the-counter (OTC) and pharmacologically based prescription-driven mucositis care products, including mouthwashes, topical gels, and oral rinses. Retail pharmacies have the added advantage of being both accessible and convenient for patients to manage mild to moderate mucositis at home. Additionally, the increasing uptake of various specialty mucositis therapies in brick-and-mortar and online storefronts is further augmenting the segment growth.
Regional Analysis:
North America dominated the oral mucositis treatment market with 39.6% market share in 2024 due to the large pool of cancer cases in North America and the extensive use of chemotherapy and radiotherapy in the region are major drivers of the oral mucositis treatment market. The region has a strong healthcare infrastructure, advanced oncology care, and early access to new therapies, including low-level laser therapy and biologics. In addition, major pharmaceutical manufacturers, well-established clinical research activities, and favorable reimbursement policies make this area a major player in the global market.
Asia Pacific is projected to be the fastest-growing region for the oral mucositis treatment market trend, as there is a sudden rise in the occurrence of incidence of cancer here, and also, the accessibility of healthcare services is getting better. Markets such as China, India, and Japan are seeing new investments in oncology care, government drives to enhance cancer treatment infrastructure, and increased patient awareness. Moreover, increasing clinical trials, healthcare expenditure, and availability of more affordable treatment options are contributing to the market growth in the region.
The oral mucositis treatment market analysis in Europe is witnessing remarkable growth on account of the growing burden of cancer, increasing usage of aggressive cancer treatments, and an expanding aging population. Rapid and new product launches, increased technological advancements and investment in research and development, growing awareness of supportive oncology care, coupled with rising acceptance of advanced products including mucosal protectants and anti-inflammatory agents, and widespread adoption among healthcare providers are expected to drive growth in this market. Furthermore, ongoing clinical research, strong regulatory support, and government-funded healthcare initiatives in key European markets are expected to continue to drive the growth of the European oral mucositis treatment market.
The oral mucositis treatment market in Latin America and the Middle East & Africa (MEA) is experiencing moderate growth. This is largely attributed to better health care infrastructure, the ongoing rise in the number of cancer diagnoses, and an increase in awareness about the complications of cancer therapies. Slower market growth is partially restrained by restricted access to more advanced treatment options, lower health care spending, and a lack of dedicated oncology care in some countries. Growth in both regions is expected to remain robust, buoyed by rising investments and health systems reforms, notwithstanding these challenges.
Key Players:
Oral mucositis treatment market companies are 3M, Colgate-Palmolive Company, Pfizer Inc., GlaxoSmithKline plc, Soligenix, Inc., EUSA Pharma, Camurus AB, Helsinn Healthcare SA, Galera Therapeutics, Inc., Amgen Inc., Clinigen Group plc, Enzychem Lifesciences Corporation, MuReva Phototherapy, Oragenics, Inc., Monopar Therapeutics Inc., Onxeo S.A., Synedgen Inc., BioAlliance Pharma SA, Midatech Pharma PLC, and other players.
Recent Developments:
-
April 2024 – Napo Pharmaceuticals made an expansion of its oncology supportive care business through the in-licensing of prescription Gelclair for the treatment of oral mucositis. The company reaffirmed plans to commercially launch FDA-approved Gelclair in Q3 2024 in patients receiving cancer treatment.
-
January 2024 – Soligenix, Inc., a late-stage biopharmaceutical firm, announced that its experimental oral mucositis drug SGX945 (dusquetide), which is for the treatment of oral lesions associated with Behçet's Disease, has been given Fast Track Designation by the U.S. Food and Drug Administration (FDA).
Oral Mucositis Treatment Market Report Scope:
Report Attributes Details Market Size in 2024 USD 1.79 Billion Market Size by 2032 USD 3.12 Billion CAGR CAGR of 7.26% From 2025 to 2032 Base Year 2024 Forecast Period 2025-2032 Historical Data 2021-2023 Report Scope & Coverage Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook Key Segments • By Treatment Type (Pain Control Medication, Mouthwash, Physical Therapies, Other Treatment Types)
• By Drug Class (Anti-Inflammatory, Antimicrobials, Antifungal, Anti-Neoplastic, Antibiotics, Other Drug Classes)
• By Cause (Chemotherapy, Radiotherapy)
• By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
• By End-Use (Hospitals and Clinics, Ambulatory Surgical Centers, Long-term Care Facilities, Homecare Settings)Regional Analysis/Coverage North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) Company Profiles Oral mucositis treatment market companies are 3M, Colgate-Palmolive Company, Pfizer Inc., GlaxoSmithKline plc, Soligenix, Inc., EUSA Pharma, Camurus AB, Helsinn Healthcare SA, Galera Therapeutics, Inc., Amgen Inc., Clinigen Group plc, Enzychem Lifesciences Corporation, MuReva Phototherapy, Oragenics, Inc., Monopar Therapeutics Inc., Onxeo S.A., Synedgen Inc., BioAlliance Pharma SA, Midatech Pharma PLC, and other players.
Table Of Contents
1. Introduction
1.1 Market Definition & Scope
1.2 Research Assumptions & Abbreviations
1.3 Research Methodology
2. Executive Summary
2.1 Market Snapshot
2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2021–2032
2.3 Market Size & Forecast, By Segmentation, 2021–2032
2.3.1 Market Size By Treatment Type
2.3.2 Market Size By Drug Class
2.3.2 Market Size By Cause
2.3.2 Market Size By Distribution Channel
2.3.2 Market Size By End-Use
2.4 Market Share & Bps Analysis By Region, 2024
2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic
2.6 Industry CxO’s Perspective
3. Market Overview
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Key Market Trends
3.2 Industry PESTLE Analysis
3.3 Key Industry Forces (Porter’s) Impacting Market Growth
3.4 Industry Supply Chain Analysis
3.4.1 Raw Material Suppliers
3.4.2 Manufacturers
3.4.3 Distributors/Suppliers
3.4.4 Customers/End-Users
3.5 Industry Life Cycle Assessment
3.6 Parent Market Overview
3.7 Market Risk Assessment
4. Statistical Insights & Trends Reporting
4.1 Incidence and Prevalence (2024)
4.1.1 Global incidence in chemotherapy- and radiotherapy-induced oral mucositis
4.1.2 Incidence by cancer type (e.g., head & neck, breast, leukemia)
4.1.3 Prevalence rates among pediatric vs. adult populations
4.1.4 Regional comparison of oral mucositis prevalence (North America, Europe, Asia-Pacific)
4.2 Prescription Trends (2024), by Region
4.2.1 Regional distribution of prescription volumes
4.2.2 Market share of branded vs. generic formulations
4.2.3 Drug class-wise prescription trends (e.g., analgesics, barrier agents, anti-inflammatory rinses)
4.2.4 Uptake of emerging therapies (e.g., mucoadhesive gels, growth factor therapies)
4.3 Product Volume and Utilization, by Region (2020–2032)
4.3.1 Annual product volume trends (2020–2032)
4.3.2 Regional product utilization comparison (North America, Europe, Asia-Pacific, Latin America)
4.3.3 Product-wise utilization breakdown (mouth rinses, gels, lozenges, cryotherapy)
4.3.4 Utilization by healthcare setting (hospital vs. homecare)
4.3.5 CAGR analysis by product type (2024–2032)
4.4 Healthcare Spending, by Region (2024)
4.4.1 Regional healthcare spending on oral mucositis treatment
4.4.2 Government vs. commercial vs. private insurance contributions
4.4.3 Out-of-pocket spending trends in emerging and developed economies
4.4.4 Economic burden per patient by country (e.g., US, Germany, India, Japan)
5. Oral Mucositis Treatment Market Segmental Analysis & Forecast, By Treatment Type, 2021 – 2032, Value (USD Billion)
5.1 Introduction
5.2 Pain Control Medication
5.2.1 Key Trends
5.2.2 Market Size & Forecast, 2021 – 2032
5.3 Mouthwash
5.3.1 Key Trends
5.3.2 Market Size & Forecast, 2021 – 2032
5.4 Physical Therapies
5.4.1 Key Trends
5.4.2 Market Size & Forecast, 2021 – 2032
5.5 Other Treatment Types
5.5.1 Key Trends
5.5.2 Market Size & Forecast, 2021 – 2032
6. Oral Mucositis Treatment Market Segmental Analysis & Forecast, By Drug Class, 2021 – 2032, Value (USD Billion)
6.1 Introduction
6.2 Anti-Inflammatory
6.2.1 Key Trends
6.2.2 Market Size & Forecast, 2021 – 2032
6.3 Antimicrobials
6.3.1 Key Trends
6.3.2 Market Size & Forecast, 2021 – 2032
6.4 Antifungal
6.4.1 Key Trends
6.4.2 Market Size & Forecast, 2021 – 2032
6.5 Anti-Neoplastic
6.5.1 Key Trends
6.5.2 Market Size & Forecast, 2021 – 2032
6.6 Antibiotics
6.6.1 Key Trends
6.6.2 Market Size & Forecast, 2021 – 2032
6.7 Other Drug Classes
6.7.1 Key Trends
6.7.2 Market Size & Forecast, 2021 – 2032
7. Oral Mucositis Treatment Market Segmental Analysis & Forecast, By Cause, 2021 – 2032, Value (USD Billion)
7.1 Introduction
7.2 Chemotherapy
7.2.1 Key Trends
7.2.2 Market Size & Forecast, 2021 – 2032
7.3 Radiotherapy
7.3.1 Key Trends
7.3.2 Market Size & Forecast, 2021 – 2032
8. Oral Mucositis Treatment Market Segmental Analysis & Forecast, By Distribution Channel, 2021 – 2032, Value (USD Billion)
8.1 Introduction
8.2 Hospital Pharmacy
8.2.1 Key Trends
8.2.2 Market Size & Forecast, 2021 – 2032
8.3 Retail Pharmacy
8.3.1 Key Trends
8.3.2 Market Size & Forecast, 2021 – 2032
8.4 Online Pharmacy
8.4.1 Key Trends
8.4.2 Market Size & Forecast, 2021 – 2032
9. Oral Mucositis Treatment Market Segmental Analysis & Forecast, By End-Use, 2021 – 2032, Value (USD Billion)
9.1 Introduction
9.2 Hospitals and Clinics
9.2.1 Key Trends
9.2.2 Market Size & Forecast, 2021 – 2032
9.3 Ambulatory Surgical Centers
9.3.1 Key Trends
9.3.2 Market Size & Forecast, 2021 – 2032
9.4 Long-term Care Facilities
9.4.1 Key Trends
9.4.2 Market Size & Forecast, 2021 – 2032
9.5 Homecare Settings
9.5.1 Key Trends
9.5.2 Market Size & Forecast, 2021 – 2032
10. Oral Mucositis Treatment Market Segmental Analysis & Forecast By Region, 2021 – 2032, Value (USD Billion)
10.1 Introduction
10.2 North America
10.2.1 Key Trends
10.2.2 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.2.3 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.2.4 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.2.5 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.2.6 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.2.7 Oral Mucositis Treatment Market Size & Forecast, By Country, 2021 – 2032
10.2.7.1 USA
10.2.7.1.1 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.2.7.1.2 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.2.7.1.3 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.2.7.1.4 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.2.7.1.5 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.2.7.2 Canada
10.2.7.2.1 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.2.7.2.2 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.2.7.2.3 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.2.7.2.4 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.2.7.2.5 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.3 Europe
10.3.1 Key Trends
10.3.2 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.3.3 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.3.4 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.3.5 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.3.6 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.3.7 Oral Mucositis Treatment Market Size & Forecast, By Country, 2021 – 2032
10.3.7.1 Germany
10.3.7.1.1 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.3.7.1.2 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.3.7.1.3 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.3.7.1.4 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.3.7.1.5 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.3.7.2 UK
10.3.7.2.1 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.3.7.2.2 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.3.7.2.3 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.3.7.2.4 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.3.7.2.5 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.3.7.3 France
10.3.7.3.1 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.3.7.3.2 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.3.7.3.3 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.3.7.3.4 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.3.7.3.5 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.3.7.4 Italy
10.3.7.4.1 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.3.7.4.2 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.3.7.4.3 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.3.7.4.4 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.3.7.4.5 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.3.7.5 Spain
10.3.7.5.1 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.3.7.5.2 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.3.7.5.3 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.3.7.5.4 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.3.7.5.5 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.3.7.6 Russia
10.3.7.6.1 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.3.7.6.2 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.3.7.6.3 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.3.7.6.4 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.3.7.6.5 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.3.7.7 Poland
10.3.7.7.1 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.3.7.7.2 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.3.7.7.3 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.3.7.7.4 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.3.7.7.5 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.3.7.8 Rest of Europe
10.3.7.8.1 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.3.7.8.2 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.3.7.8.3 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.3.7.8.4 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.3.7.8.5 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.4 Asia-Pacific
10.4.1 Key Trends
10.4.2 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.4.3 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.4.4 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.4.5 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.4.6 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.4.7 Oral Mucositis Treatment Market Size & Forecast, By Country, 2021 – 2032
10.4.7.1 China
10.4.7.1.1 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.4.7.1.2 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.4.7.1.3 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.4.7.1.4 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.4.7.1.5 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.4.7.2 India
10.4.7.2.1 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.4.7.2.2 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.4.7.2.3 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.4.7.2.4 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.4.7.2.5 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.4.7.3 Japan
10.4.7.3.1 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.4.7.3.2 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.4.7.3.3 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.4.7.3.4 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.4.7.3.5 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.4.7.4 South Korea
10.4.7.4.1 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.4.7.4.2 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.4.7.4.3 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.4.7.4.4 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.4.7.4.5 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.4.7.5 Australia
10.4.7.5.1 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.4.7.5.2 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.4.7.5.3 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.4.7.5.4 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.4.7.5.5 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.4.7.6 ASEAN Countries
10.4.7.6.1 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.4.7.6.2 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.4.7.6.3 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.4.7.6.4 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.4.7.6.5 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.4.7.7 Rest of Asia-Pacific
10.4.7.7.1 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.4.7.7.2 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.4.7.7.3 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.4.7.7.4 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.4.7.7.5 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.5 Latin America
10.5.1 Key Trends
10.5.2 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.5.3 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.5.4 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.5.5 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.5.6 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.5.7 Oral Mucositis Treatment Market Size & Forecast, By Country, 2021 – 2032
10.5.7.1 Brazil
10.5.7.1.1 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.5.7.1.2 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.5.7.1.3 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.5.7.1.4 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.5.7.1.5 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.5.7.2 Argentina
10.5.7.2.1 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.5.7.2.2 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.5.7.2.3 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.5.7.2.4 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.5.7.2.5 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.5.7.3 Mexico
10.5.7.3.1 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.5.7.3.2 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.5.7.3.3 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.5.7.3.4 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.5.7.3.5 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.5.7.4 Colombia
10.5.7.4.1 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.5.7.4.2 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.5.7.4.3 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.5.7.4.4 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.5.7.4.5 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.5.7.5 Rest of Latin America
10.5.7.5.1 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.5.7.5.2 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.5.7.5.3 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.5.7.5.4 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.5.7.5.5 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.6 Middle East & Africa
10.6.1 Key Trends
10.6.2 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.6.3 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.6.4 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.6.5 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.6.6 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.6.7 Oral Mucositis Treatment Market Size & Forecast, By Country, 2021 – 2032
10.6.7.1 UAE
10.6.7.1.1 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.6.7.1.2 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.6.7.1.3 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.6.7.1.4 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.6.7.1.5 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.6.7.2 Saudi Arabia
10.6.7.2.1 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.6.7.2.2 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.6.7.2.3 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.6.7.2.4 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.6.7.2.5 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.6.7.3 Qatar
10.6.7.3.1 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.6.7.3.2 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.6.7.3.3 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.6.7.3.4 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.6.7.3.5 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.6.7.4 Egypt
10.6.7.4.1 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.6.7.4.2 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.6.7.4.3 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.6.7.4.4 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.6.7.4.5 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.6.7.5 South Africa
10.6.7.5.1 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.6.7.5.2 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.6.7.5.3 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.6.7.5.4 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.6.7.5.5 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
10.6.7.6 Rest of Middle East & Africa
10.6.7.6.1 Oral Mucositis Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.6.7.6.2 Oral Mucositis Treatment Market Size & Forecast, By Drug Class, 2021 – 2032
10.6.7.6.3 Oral Mucositis Treatment Market Size & Forecast, By Cause, 2021 – 2032
10.6.7.6.4 Oral Mucositis Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.6.7.6.5 Oral Mucositis Treatment Market Size & Forecast, By End-Use, 2021 – 2032
11. Competitive Landscape
11.1 Key Players' Positioning
11.2 Competitive Developments
11.2.1 Key Strategies Adopted (%), By Key Players, 2024
11.2.2 Year-Wise Strategies & Development, 2021 – 2025
11.2.3 Number Of Strategies Adopted By Key Players, 2024
11.3 Market Share Analysis, 2024
11.4 Product/Service & Application Benchmarking
11.4.1 Product/Service Specifications & Features By Key Players
11.4.2 Product/Service Heatmap By Key Players
11.4.3 Application Heatmap By Key Players
11.5 Industry Start-Up & Innovation Landscape
11.6 Key Company Profiles
11.6 Key Company Profiles
11.6.1 3M
11.6.1.1 Company Overview & Snapshot
11.6.1.2 Product/Service Portfolio
11.6.1.3 Key Company Financials
11.6.1.4 SWOT Analysis
11.6.2 Colgate-Palmolive Company
11.6.2.1 Company Overview & Snapshot
11.6.2.2 Product/Service Portfolio
11.6.2.3 Key Company Financials
11.6.2.4 SWOT Analysis
11.6.3 Pfizer Inc.
11.6.3.1 Company Overview & Snapshot
11.6.3.2 Product/Service Portfolio
11.6.3.3 Key Company Financials
11.6.3.4 SWOT Analysis
11.6.4 GlaxoSmithKline plc
11.6.4.1 Company Overview & Snapshot
11.6.4.2 Product/Service Portfolio
11.6.4.3 Key Company Financials
11.6.4.4 SWOT Analysis
11.6.5 Soligenix, Inc.
11.6.5.1 Company Overview & Snapshot
11.6.5.2 Product/Service Portfolio
11.6.5.3 Key Company Financials
11.6.5.4 SWOT Analysis
11.6.6 EUSA Pharma
11.6.6.1 Company Overview & Snapshot
11.6.6.2 Product/Service Portfolio
11.6.6.3 Key Company Financials
11.6.6.4 SWOT Analysis
11.6.7 Camurus AB
11.6.7.1 Company Overview & Snapshot
11.6.7.2 Product/Service Portfolio
11.6.7.3 Key Company Financials
11.6.7.4 SWOT Analysis
11.6.8 Helsinn Healthcare SA
11.6.8.1 Company Overview & Snapshot
11.6.8.2 Product/Service Portfolio
11.6.8.3 Key Company Financials
11.6.8.4 SWOT Analysis
11.6.9 Galera Therapeutics, Inc.
11.6.9.1 Company Overview & Snapshot
11.6.9.2 Product/Service Portfolio
11.6.9.3 Key Company Financials
11.6.9.4 SWOT Analysis
11.6.10 Amgen Inc.
11.6.10.1 Company Overview & Snapshot
11.6.10.2 Product/Service Portfolio
11.6.10.3 Key Company Financials
11.6.10.4 SWOT Analysis
11.6.11 Clinigen Group plc
11.6.11.1 Company Overview & Snapshot
11.6.11.2 Product/Service Portfolio
11.6.11.3 Key Company Financials
11.6.11.4 SWOT Analysis
11.6.12 Enzychem Lifesciences Corporation
11.6.12.1 Company Overview & Snapshot
11.6.12.2 Product/Service Portfolio
11.6.12.3 Key Company Financials
11.6.12.4 SWOT Analysis
11.6.13 MuReva Phototherapy
11.6.13.1 Company Overview & Snapshot
11.6.13.2 Product/Service Portfolio
11.6.13.3 Key Company Financials
11.6.13.4 SWOT Analysis
11.6.14 Oragenics, Inc.
11.6.14.1 Company Overview & Snapshot
11.6.14.2 Product/Service Portfolio
11.6.14.3 Key Company Financials
11.6.14.4 SWOT Analysis
11.6.15 Monopar Therapeutics Inc.
11.6.15.1 Company Overview & Snapshot
11.6.15.2 Product/Service Portfolio
11.6.15.3 Key Company Financials
11.6.15.4 SWOT Analysis
11.6.16 Onxeo S.A.
11.6.16.1 Company Overview & Snapshot
11.6.16.2 Product/Service Portfolio
11.6.16.3 Key Company Financials
11.6.16.4 SWOT Analysis
11.6.17 Synedgen Inc.
11.6.17.1 Company Overview & Snapshot
11.6.17.2 Product/Service Portfolio
11.6.17.3 Key Company Financials
11.6.17.4 SWOT Analysis
11.6.18 BioAlliance Pharma SA
11.6.18.1 Company Overview & Snapshot
11.6.18.2 Product/Service Portfolio
11.6.18.3 Key Company Financials
11.6.18.4 SWOT Analysis
11.6.19 Midatech Pharma PLC
11.6.19.1 Company Overview & Snapshot
11.6.19.2 Product/Service Portfolio
11.6.19.3 Key Company Financials
11.6.19.4 SWOT Analysis
12. Analyst Recommendations
12.1 SNS Insider Opportunity Map
12.2 Industry Low-Hanging Fruit Assessment
12.3 Market Entry & Growth Strategy
12.4 Analyst Viewpoint & Suggestions On Market Growth
13. Assumptions
14. Disclaimer
15. Appendix
15.1 List Of Tables
15.2 List Of Figures
Key Segments:
By Treatment Type
- Pain Control Medication
- Mouthwash
- Physical Therapies
- Other Treatment Types
By Drug Class
- Anti-Inflammatory
- Antimicrobials
- Antifungal
- Anti-Neoplastic
- Antibiotics
- Other Drug Classes
By Cause
- Chemotherapy
- Radiotherapy
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By End-Use
- Hospitals and Clinics
- Ambulatory Surgical Centers
- Longterm Care Facilities
- Homecare Settings
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
- US
- Canada
Europe
- Germany
- France
- UK
- Italy
- Spain
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- ASEAN Countries
- Rest of Asia Pacific
Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- Egypt
- South Africa
- Rest of Middle East & Africa
Latin America
- Brazil
- Argentina
- Mexico
- Colombia
- Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
- Detailed Volume Analysis
- Criss-Cross segment analysis (e.g., Product X Application)
- Competitive Product Benchmarking
- Geographic Analysis
- Additional countries in any of the regions
- Customized Data Representation
- Detailed analysis and profiling of additional market players
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
